



“LUNG FUNCTION TESTS IN PATIENTS OF PREDIABETES AND DIABETES”

Physiology

Ishtiaq Ahmad Sofi Demonstrator Department of Physiology, Govt. Medical College Srinagar, J&K, India.

Suhail Ahmad Gilkar* Associate Professor Department of Physiology, Govt. Medical College Srinagar, J&K, India. *Corresponding Author

Masood Tanvir Professor Department of Medicine, Govt. Medical College Srinagar, J&K, India.

ABSTRACT

Background: Prediabetes is a condition where people have blood glucose levels higher than normal but not yet high enough to be diagnosed with diabetes. WHO divides prediabetes into impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). Prediabetes is a common disorder in most populations¹. Before people develop Type 2 diabetes, they almost always have prediabetes². Pulmonary Function Testing (PFT) is a complete evaluation of the respiratory system including patient history, physical examination, chest x-ray examinations, arterial blood gas (ABG) analysis and spirometry. Spirometry is the recommended objective test performed to identify abnormalities in lung volumes and air flow³. Accumulating evidence suggests that there is a close relationship between impaired lung function and diabetes mellitus (DM). Population-based studies have demonstrated associations between both obstructive and restrictive lung impairment and insulin resistance or DM^{4,5}. A number of Asian studies have also revealed a significant association between reduced lung function and insulin resistance, metabolic syndrome and type 2 diabetes^{6,7}.

Aims and objectives: To assess lung function in patients of Prediabetes and diabetes by spirometry.

Materials and methods: Our study was an observational cross sectional study. 1179 apparently healthy non-smoker adult subjects underwent fasting plasma glucose (FPG) test, 2-hr oral glucose tolerance test (OGTT) and spirometry. The spirometric parameters measured were percent predicted values of FVC (forced vital capacity), FEV₁ (forced expiratory volume in 1 second), and FEV₁/FVC. On the basis of FPG and 2 hr. OGTT the subjects were divided into NGT (normal glucose tolerance), Prediabetes and Diabetes groups.

Results: In this study 870 (74%) subjects had NGT, 177 (15%) had prediabetes and 132 (11%) had diabetes. FVC (% pred.) and FEV₁ (% pred.) were significantly lower but FEV₁/FVC (% pred.) was significantly higher in prediabetes and diabetes groups as compared to NGT group.

Conclusion: Restrictive lung disease (low lung volume) was significantly associated with prediabetes and diabetes.

KEYWORDS

Prediabetes, diabetes, lung function tests, spirometry.

1. Introduction

Prediabetes is a condition where people have blood glucose levels higher than normal but not yet high enough to be diagnosed with diabetes. It is a stage of intermediate hyperglycemia between normal glucose tolerance and type 2 diabetes. WHO divides prediabetes into impaired glucose tolerance (IGT) and impaired fasting glucose (IFG)⁸. Both IFG and IGT are the established risk factors for diabetes mellitus⁹. Prediabetes is a common disorder in most populations. Before people develop Type 2 diabetes, they almost always have prediabetes. There is progressive impairment of insulin secretion (or β -cell dysfunction) as well as worsening insulin resistance, in people with prediabetes¹⁰, resulting in gradual increases in fasting and post-prandial plasma glucose concentrations. The higher the glucose values, the greater the risk of progression to diabetes and diabetic complications. Progression to overt diabetes from a prediabetes state occurs gradually over a period of many years and is characterized by worsening insulin resistance and insulin secretory dysfunction and gradual increase in fasting and postprandial plasma glucose concentrations^{11,12,13}.

Pulmonary Function Testing (PFT) is a complete evaluation of the respiratory system including patient history, physical examination, chest x-ray examinations, arterial blood gas (ABG) analysis and spirometry. Spirometry is the recommended objective test performed to identify abnormalities in lung volumes and air flow³. In obstructive diseases (asthma, COPD, chronic bronchitis, emphysema), FEV₁ is diminished because of increased airway resistance to expiratory flow; the FVC may be decreased as well due to premature closure of airways in expiration, but not in the same proportion as FEV₁. In restrictive diseases e.g. pulmonary fibrosis, the FEV₁ and FVC are both reduced proportionately and the value may be normal or even increased as a result of decreased lung compliance. Accumulating evidence suggests that there is a close relationship between impaired lung function and diabetes mellitus (DM). The association of reduced lung function and diabetes has been described for many years^{4,5}. Population-based studies have demonstrated associations between both obstructive and restrictive lung impairment and insulin resistance or DM. A number of Asian studies have also revealed a significant association between reduced lung function and insulin resistance, metabolic syndrome and type 2 diabetes^{6,7}.

2. Materials and Methods

The present study was undertaken in young Kashmiri adult population. It was a cross-sectional observational study. The group consisted of both males and females of age 18 years and above. A total of 1179 subjects participated in our study.

All the subjects underwent fasting plasma glucose (FPG) estimation, 2-hour oral glucose tolerance test (OGTT) and spirometry. Blood sugar estimation of the samples was done using automatic biochemistry analyzer Hitachi 912. On the basis of FPG and 2-hr. OGTT, subjects were classified into five categories as per American Diabetes Association criteria (ADA)¹⁴:

1. Isolated IFG (FPG 100–125 mg/dl and 2-h OGTT < 140 mg/dl).
2. Isolated IGT (FPG < 100 mg/dl and 2-h OGTT 140–199 mg/dl).
3. Combined IFG/IGT (FPG 100–125 mg/dl and 2-h OGTT 140–199 mg/dl).
4. Diabetes (FPG \geq 126 mg/dl or 2-h OGTT \geq 200 mg/dl).
5. Normal glucose tolerance [NGT] (FPG < 100 mg/dl and 2-h OGTT < 140 mg/dl).

Isolated IFG, Isolated IGT and combined IFG & IGT were considered as subgroups of prediabetes. All the subjects underwent spirometry as per American Thoracic Society (ATS) standards. FVC (% pred.), FEV₁ (% pred.) and FEV₁/FVC (% pred.) were determined. FVC and FEV₁ (% pred.) \geq 80% were considered as normal. FEV₁/FVC (% pred.) \geq 70% was considered as normal. Pulmonary function was measured using RMS Helios 701 Spirometer.

Results

The total number of subjects in our study was 1179. Out of total 1179 subjects, 412 (35%) were males and 767 (65%) were females. Out of the total 1179 subjects, 870 (74%) had NGT, 177 (15%) had prediabetes and 132 (11%) had diabetes.

FVC (% pred.) and FEV₁ (% pred.) were significantly lower while as FEV₁/FVC (% pred.) was significantly higher in prediabetics and diabetics as compared to NGT group subjects. The trend was followed by all the three subgroups of prediabetes. Age and BMI were significantly higher in prediabetics and diabetics as compared to NGT

group subjects. These results of this study point towards a predominantly restrictive pattern (low lung volume) of lung dysfunction in prediabetic and diabetic groups as compared to NGT group.

Table 1

Distribution of study subjects according to gender

Gender	Number	Percentage (%)
Male	412	35
Female	767	65
Total	1179	100

Table 2

Comparison of Age, BMI and spirometric parameters of Prediabetic and Diabetic groups with those of NGT group.

	NGT	Prediabetes	Diabetes	p-value
Number of subjects	870	177	132	
Age(years)	39.20±13.90	47.90±14.20	48.70 ± 16.50	<0.001
BMI(kg/m ²)	23.97 ± 4.10	26.97 ± 4.57	25.95 ± 4.61	<0.001
FVC (% pred.)	108.75±13.86	83.05±12.48	76.23± 8.93	<0.001
FEV ₁ (% pred.)	120.74±15.44	97.21±14.88	89.52± 10.79	<0.001
FEV ₁ /FVC(%pred.)	111.61±11.09	117.34±10.41	117.36± 8.63	<0.001

NGT=normal glucose tolerance; BMI=body mass index; FVC=forced vital capacity; FEV₁=forced expiratory volume in 1 second. Values are numbers or Mean±SD; p<0.05 was considered statistically significant.

Table 3

Comparison of spirometric parameters of Prediabetic subgroups with those of NGT group.

	NGT	Isolated IFG	Isolated IGT	Combined IFG& IGT	p-value
Number of subjects	870	56	54	67	
FVC (% pred.)	108.75±13.86	88.45±11.18	86.69±10.82	75.60±11.21	<0.001
FEV ₁ (% pred.)	120.74±15.44	102.63±14.44	99.98±13.25	90.45±14.33	<0.001
FEV ₁ /FVC(% pred.)	111.61±11.09	116.25±10.36	115.30±10.40	119.91±10.11	<0.001

NGT=normal glucose tolerance; FVC=forced vital capacity; FEV₁=forced expiratory volume in 1 second; IFG=impaired fasting glucose; IGT=impaired glucose tolerance. Values are numbers or Mean±SD; p<0.05 was considered statistically significant.

Discussion

Prediabetes is a global health problem. The prevalence of prediabetes is in fact higher than the diabetes prevalence. The person who develops prediabetes is going to become diabetic if he/she goes untreated in an appropriate manner¹⁵. Diabetes is a micro- macrovascular disorder with debilitating effects on many organs. It is known to cause target organ diseases like nephropathy, retinopathy and neuropathy. The alveolar capillary network in the lungs is a large microvascular unit and may be affected by microangiopathy. However because of its large reserve, substantial loss of the microvascular bed can be tolerated without developing dyspnea. As a result pulmonary diabetic microangiopathy may be under- recognized clinically. Reduced elastic recoil, reduced lung volume, diminished respiratory muscle performance, chronic low grade inflammation¹⁶, decrease in pulmonary diffusion capacity for carbon monoxide, autonomic neuropathy involving respiratory muscles are some of the important changes occurring in DM.

The mechanism by which impaired glycemic control may lead to a reduction in lung function is uncertain, though it has been suggested that the increased systemic inflammation associated with diabetes may result in pulmonary inflammation and hence airway damage¹⁷.

Alternatively, a reduction in antioxidant defenses resulting from increased oxidative activity associated with diabetes may lead to a

secondary reduction in the antioxidant defenses of the lung and hence increased susceptibility to environmental oxidative insults, resulting in subsequent loss of lung function. While IFG is characterized by predominantly hepatic insulin resistance and normal muscle insulin sensitivity, IGT shows normal to slightly reduced hepatic insulin sensitivity and moderate to severe muscle insulin resistance. Both IFG and IGT are associated with impairment of insulin secretion.

The histopathological changes in the lungs of diabetics are associated with the thickening of the alveolar epithelium and the pulmonary capillary basal lamina and also reduced recoiling of the lung. This is caused by biochemical alteration of connective tissue constituents, particularly collagen and elastin. There is increased cross-linkage formation between polypeptides of collagen which leads to thickening, leading to restriction of lung volume and alveolar gas transport, reduced membrane diffusion capacity and pulmonary capillary blood volume.

Our study results are consistent with the study results of Takashi Yamane, Akihito Yokoyama, Yoshihiro Kitahara, et al (2013),¹⁸ that low % FVC but not low FEV₁/FVC ratio was significantly associated with increased prevalence's of diabetes and prediabetes in the cross-sectional study. Our study results are in agreement with the study results of Yulan Li, Masafumi Saito, Satoshi Tobimatsu et al(2013),¹⁹ which showed that the prevalence of low FVC increased significantly with progression from NGT to diabetes, whereas the prevalence of low FEV₁/FVC did not. Not only diabetes but also prediabetes was significantly associated with low FVC, compared with NGT. Isolated IFG, combined IFG & IGT, and diabetes were significantly associated with low FVC.

Cross sectional study results of Mahadeva Murthy, et al (2012)²⁰ showed that the spirometric values were consistently lower in subjects with Type 2 diabetes mellitus than in non-diabetics. The differences reached statistical significance only for FVC, but the trend was seen across all parameters. The results of our study also demonstrated that the spirometric findings were consistently lower in diabetics than in non-diabetics. However our study results reached statistical significance for FEV₁ also.

Our study results are in agreement with the study results of Bram van den Borst, Harry R. Gosker, Maurice P. Zeegers, et al(2010)²¹, that in the absence of covert pulmonary comorbidity both type I and type II diabetes are associated with a modest, albeit statistically significant, impaired pulmonary function in a restrictive pattern. However, we did not categorize diabetics into Type I and Type II.

Muhammad Irfan, Abdul Jabbar, Ahmad Suleman Haque, et al(2011)²², on studying the effects of DM on lung function concluded that there was a significant reduction in FVC and FEV₁ in diabetics as compared to controls and there was no significant difference in FEV₁/FVC between two groups. Our study also demonstrated a significant reduction in FVC and FEV₁ in diabetics but in our study FEV₁/FVC was significantly higher in diabetics as compared to controls.

CONCLUSION

Restrictive lung disease (low lung volume) was significantly associated with prediabetes and diabetes. The severity of lung restriction increased gradually with progressively increasing blood glucose levels. Spirometry remains a cost effective; a simple non-invasive method for assessing extent of pulmonary involvement in prediabetics and diabetics and its judicious use can help in measuring the response to treatment in these states.

REFERENCES

- Nathan DM et al. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. *Diabetes Care* 2007; 30: 753-759.
- American College of Endocrinology Consensus Statement on the diagnosis and management of pre-diabetes in the continuum of hyperglycemia – when do the risk of diabetes begin? July 23, 2008.
- Pierce, R. Spirometry: An essential clinical measurement? *Australian Family Physician* 2005; 34(7): 535-539.
- Engström G, Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. *Diabet Med* 2002; 19: 167–70.
- Kwon CH, Rhee EJ, Song JU, et al. Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men. *Cardiovasc Diabetol* 2012; 11: 38.
- Oda E, Kawai R.A cross-sectional relationship between vital capacity and metabolic syndrome and between vital capacity and diabetes in a sample Japanese population. *Environ Health Prev Med* 2009; 14: 284–291.
- Lim SY, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. *J*

- Korean Med Sci 2010; 25: 1480–1486.
8. World Health Organisation Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia report of a WHO/IDF consultation Geneva: WHO, 2006.
 9. Nicholas GA, Hillier TA, Brown JB. Progression from Newly Acquired Impaired Fasting Glucose to Type 2 Diabetes. *Diabetes Care* 2007; 30(2): 228-233.
 10. Buchanan TA et al. Diabetes. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. 2002 Sep; 51(9): 2796-803.
 11. Abdul Ghani M.A., De Fronzo. R.A. Pathophysiology of prediabetes. *Curr Diab Rep* 2009; 9: 193-199.
 12. Pratley R.E., Weyer C, et al. The role of impaired early insulin secretion in the pathogenesis of Type 2 DM *Diabetologia* 2001; 44: 929-945.
 13. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 DM. *J Clin Invest* 1999; 104: 787-794.
 14. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med* 2002; 19: 708-723.
 15. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia- When Do the risks of Diabetes Begin? A Consensus Statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. *Endocr Pract* 2008; 14(7): 933-46.
 16. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: A prospective study. *Thorax* 2007; 62: 515-20.
 17. Walter R, Beiser A, Givelber R, et al. The association between glycemic state and lung function: The Framingham Heart Study. *Am J Respir Crit Care Med* 2003; 167: 911–16.
 18. Takashi Yamane, Akihito Yokoyama, Yoshihiro Kitahara, et al. Cross-sectional and prospective study of the association between lung function and prediabetes. *BMJ Open* 2013; 3: e002179.
 19. Yulan Li, Masafumi Saito, Satoshi Tobimatsu, et al. Prediabetes and impaired lung function in asymptomatic adults. *Diabetes Research and Clinical Practice* 2013; 100: e 51- e 54.
 20. Mahadeva Murthy, et al. Changes in Lung Function Tests in Type-2 Diabetes Mellitus; *International Journal of Basic Medical Science* June 2012; Vol. 3, Issue 2: 54-58.
 21. Bram van den Borst, Harry R. Gosker, Maurice P. Zeegers et al. Pulmonary Function in Diabetes, A metaanalysis. *Chest* 2010; 138(2): 393-406.
 22. Muhammad Irfan, Abdul Jabbar, Ahmad Suleman Haque, et al. *Lung India* 2011; 28(2): 89-92.